HCV NS5A sequencing
Source: NCBI BioProject (ID PRJDB2979)
Source: NCBI BioProject (ID PRJDB2979)
0 0
Project name: Hepatitis C virus subtype 1b
Description: Recent advances in interferon-free treatment could lead to the eradication of HCV from patients infected with HCV. One of the direct-acting anti-viral agents, HCV NS5A inhibitor is available for these combination therapies. However, naturally occurring resistance-associated variants (RAVs) to HCV NS5A inhibitors in treatment-na?ve patients with chronic hepatitis C are still unknown. Here, we performed ultra-deep sequencing and analyzed previously reported RAVs in a total 132 HCV genotype 1b-infected Japanese patients who had never used HCV NS5A inhibitors. We also performed direct-sequencing by Sanger method and examined the differences between the results of the two methods.
Data type: Targeted Locus (Loci)
Sample scope: Multiisolate
Relevance: Medical
Organization: Yamanashi Prefectural Central Hospital
Release date: 2014-09-30
Last updated: 2014-07-16